{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:58:59Z","timestamp":1790769539206,"version":"4.1.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"vor","delay-in-days":1104,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,21]]},"DOI":"10.1093\/eurheartj\/eht375","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T20:21:42Z","timestamp":1380140502000},"page":"209-215","source":"Crossref","is-referenced-by-count":223,"title":["Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention"],"prefix":"10.1093","volume":"35","author":[{"given":"D\u00e1niel","family":"Aradi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Heart Center Balatonf\u00fcred, 2 Gy\u00f3gy t\u00e9r, Balatonf\u00fcred 8230, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Science, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Kom\u00f3csi","sequence":"additional","affiliation":[{"name":"University of P\u00e9cs, Heart Institute, P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Trenk","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts-Herzzentrum Freiburg-Bad Krozingen, Klinik f\u00fcr Kardiologie und Angiologie II, Bad Krozingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Gulba","sequence":"additional","affiliation":[{"name":"Department for Internal Medicine and Cardiology, KKO St Marien-Hospital, Oberhausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3bert G\u00e1bor","family":"Kiss","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Medical Center, Military Hospital, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen","family":"Husted","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bonello","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Cardiologie, H\u00f4pital Universitaire Nord, Aix-Marseille Universit\u00e9, Inserm UMRS 608, AP-HM, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sibbing","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-University M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[{"name":"Institut de Cardiologie, INSERM UMRS937, Piti\u00e9-Salp\u00eatri\u00e8re Hospital (AP-HP), Universit\u00e9 Paris, Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[{"name":"3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Working Group on Thrombosis of the European Society of Cardiology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,9,25]]},"reference":[{"key":"key\n\t\t\t\t20180328181452_EHT375C1","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C2","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C3","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2012.11.040","article-title":"Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, Co-medications (including proton pump inhibitors), and pre-existent variability in platelet function","volume":"61","author":"Frelinger","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C5","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","article-title":"2012 ACCF\/AHA focused update of the guideline for the management of patients with unstable angina\/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"60","author":"Jneid","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C7","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328181452_EHT375C9","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C10","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328181452_EHT375C11","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C12","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease","volume":"28","author":"Lordkipanidze","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C13","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/eurheartj\/ehm232","article-title":"Laboratory detection of \u2018aspirin resistance\u2019: what test should we use (if any)?","volume":"28","author":"Cattaneo","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pcad.2009.05.001","article-title":"Aspirin resistance","volume":"52","author":"Tantry","year":"2009","journal-title":"Prog Cardiovasc Dis"},{"key":"key\n\t\t\t\t20180328181452_EHT375C15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C16","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/eurheartj\/ehp295","article-title":"Personalized medicine and antiplatelet therapy: ready for prime time?","volume":"30","author":"Verstuyft","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C17","first-page":"287","article-title":"Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients","volume":"104","author":"Paniccia","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328181452_EHT375C18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1538-7836.2011.04604.x","article-title":"High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?","volume":"10","author":"Jeong","year":"2012","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180328181452_EHT375C19","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/j.1538-7836.2007.02609.x","article-title":"Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events","volume":"5","author":"Bonello","year":"2007","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180328181452_EHT375C20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1160\/TH07-05-0324","article-title":"The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis","volume":"98","author":"Blindt","year":"2007","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328181452_EHT375C21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1160\/TH11-02-0077","article-title":"Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events","volume":"106","author":"Freynhofer","year":"2011","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328181452_EHT375C22","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328181452_EHT375C24","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328181452_EHT375C25","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C26","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjcard.2009.06.007","article-title":"Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients","volume":"104","author":"Cuisset","year":"2009","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C27","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.2011.1332","article-title":"High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI","volume":"306","author":"Parodi","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328181452_EHT375C28","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/eurheartj\/ehl275","article-title":"Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation","volume":"27","author":"Geisler","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C29","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2006.06.065","article-title":"Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement","volume":"48","author":"Hochholzer","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C30","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","article-title":"Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease","volume":"50","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/09537100802351065","article-title":"Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target","volume":"19","author":"Gurbel","year":"2008","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20180328181452_EHT375C32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ahj.2010.06.004","article-title":"Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis","volume":"160","author":"Aradi","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C33","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1538-7836.2010.03809.x","article-title":"Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis","volume":"8","author":"Combescure","year":"2010","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180328181452_EHT375C34","first-page":"841","article-title":"Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis","volume":"103","author":"Sofi","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328181452_EHT375C35","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C36","doi-asserted-by":"crossref","first-page":"E291","DOI":"10.1016\/S0735-1097(12)60292-7","article-title":"Impact of Point-of-Care Platelet Function Testing among Patients with and without Acute Coronary Syndromes Undergoing PCI with Drug-Eluting Stents: an Adapt-Des Substudy","volume":"59","author":"Kirtane","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C37","first-page":"109","article-title":"Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures","volume":"0","author":"Dahlen","year":"2012","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180328181452_EHT375C38","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C39","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.amjcard.2009.01.341","article-title":"Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"103","author":"Price","year":"2009","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180328181452_EHT375C41","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","article-title":"Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization","volume":"120","author":"Frelinger","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C42","doi-asserted-by":"crossref","first-page":"e000703","DOI":"10.1161\/JAHA.112.000703","article-title":"High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)","volume":"1","author":"Pettersen","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20180328181452_EHT375C43","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328181452_EHT375C44","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2012.17312","article-title":"Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy","volume":"308","author":"Gurbel","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328181452_EHT375C45","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1161\/CIRCULATIONAHA.111.085464","article-title":"Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study","volume":"125","author":"Reny","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C47","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/eurheartj\/ehs042","article-title":"Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response","volume":"33","author":"Gong","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C48","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328181452_EHT375C49","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C50","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2217\/pgs.11.73","article-title":"Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention","volume":"12","author":"Rideg","year":"2011","journal-title":"Pharmacogenomics"},{"key":"key\n\t\t\t\t20180328181452_EHT375C51","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328181452_EHT375C52","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328181452_EHT375C53","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis","volume":"56","author":"Hulot","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C54","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328181452_EHT375C55","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328181452_EHT375C56","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C57","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328181452_EHT375C58","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.ijcard.2012.05.100","article-title":"Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis","volume":"167","author":"Aradi","year":"2013","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C59","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328181452_EHT375C60","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328181452_EHT375C61","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jcin.2012.07.016","article-title":"Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial","volume":"5","author":"Yu","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328181452_EHT375C62","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C63","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328181452_EHT375C64","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","article-title":"Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study","volume":"115","author":"Angiolillo","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C65","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease","volume":"306","author":"Mega","year":"2011","journal-title":"JAMA"},{"issue":"Suppl. A)","key":"key\n\t\t\t\t20180328181452_EHT375C66","first-page":"A477","article-title":"Optimizing P2Y12-receptor inhibition in acute coronary syndrome patients after PCI using platelet function testing: impact of prasugrel versus high-dose clopidogrel","volume":"61","author":"Aradi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C67","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/CIRCULATIONAHA.108.833236","article-title":"Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and\/or Resistance to Clopidogrel study","volume":"119","author":"Valgimigli","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C68","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jcin.2008.08.018","article-title":"Glycoprotein IIb\/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study","volume":"1","author":"Cuisset","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328181452_EHT375C69","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization","volume":"31","author":"Wijns","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328181452_EHT375C70","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328181452_EHT375C71","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archinternmed.2012.4026","article-title":"Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials","volume":"172","author":"Komocsi","year":"2012","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180328181452_EHT375C72","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C73","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328181452_EHT375C74","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","article-title":"Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement","volume":"8","author":"Sibbing","year":"2010","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180328181452_EHT375C75","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180328181452_EHT375C76","article-title":"Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy","author":"Cuisset","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C77","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcin.2012.09.012","article-title":"Switching acute coronary syndrome patients from prasugrel to clopidogrel","volume":"6","author":"Kerneis","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180328181452_EHT375C78","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2010.03.048","article-title":"Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window","volume":"56","author":"Sibbing","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C79","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"Campo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328181452_EHT375C80","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4244\/51","article-title":"Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?","volume":"5","author":"Cuisset","year":"2009","journal-title":"EuroIntervention"},{"key":"key\n\t\t\t\t20180328181452_EHT375C81","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328181452_EHT375C82","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/35\/4\/209\/17354708\/eht375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T17:00:52Z","timestamp":1688490052000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/35\/4\/209\/465877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,25]]},"references-count":82,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,9,25]]},"published-print":{"date-parts":[[2014,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/eht375","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,1,21]]},"published":{"date-parts":[[2013,9,25]]}}}